A rare but potentially life-threatening vascular condition affecting the liver's drainage system is no longer an absolute barrier to pregnancy, thanks to evolving therapeutic approaches that have transformed maternal and fetal outcomes over the past decade. Women diagnosed with Budd-Chiari syndrome—where blood clots block the hepatic veins draining the liver—historically faced strict pregnancy contraindications due to catastrophic risks including liver failure and maternal death.
Clinical advances now enable careful pregnancy management through multiple intervention pathways. Anticoagulation therapy forms the therapeutic foundation, preventing clot progression during pregnancy's naturally hypercoagulable state. When medical therapy proves insufficient, specialized radiological procedures including hepatic vein stenting and transjugular intrahepatic portosystemic shunts can restore liver drainage, though radiation exposure requires careful dose optimization. For cases progressing to acute liver failure, liver transplantation remains viable, achieving favorable maternal survival despite suboptimal fetal outcomes.
This therapeutic evolution reflects broader improvements in managing rare thrombotic disorders during pregnancy, where individualized risk stratification has replaced blanket contraindications. The syndrome's diagnostic challenge—often masquerading as pregnancy-specific liver conditions like HELLP syndrome or acute fatty liver—underscores the critical importance of specialized hepatology expertise in pregnancy care. While outcomes have dramatically improved, successful management still requires preconceptional optimization, including thrombophilia screening and baseline liver function assessment. These developments represent a paradigm shift from pregnancy prohibition to carefully orchestrated multidisciplinary management, offering hope to women with this complex vascular condition who desire pregnancy while acknowledging the continued need for high-risk obstetric and hepatology expertise.